Based on the Relay Therapeutics Inc stock forecast from 4 analysts, the average analyst target price for Relay Therapeutics Inc is USD 18.43 over the next 12 months. Relay Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Relay Therapeutics Inc is Slightly Bearish, which is based on 3 positive signals and 5 negative signals. At the last closing, Relay Therapeutics Inc’s stock price was USD 2.05. Relay Therapeutics Inc’s stock price has changed by -21.76% over the past week, -40.75% over the past month and -71.49% over the last year.
No recent analyst target price found for Relay Therapeutics Inc
No recent average analyst rating found for Relay Therapeutics Inc
Company Overview Relay Therapeutics Inc
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Read Less
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lea...Read More
Frequently Asked Questions About Relay Therapeutics Inc (RLAY) Stock
Based on ratings from 4 analysts Relay Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 7 buy, sell and hold ratings.
Unfortunately we do not have enough data on RLAY's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for RLAY is USD 18.43 over the next 12 months. The maximum analyst target price is USD 23 while the minimum anlayst target price is USD 16.
Unfortunately we do not have enough data on RLAY's stock to indicate if its overvalued.
The last closing price of RLAY's stock was USD 2.05.
The most recent market capitalization for RLAY is USD 0.59B.
Based on targets from 4 analysts, the average taret price for RLAY is projected at USD 18.43 over the next 12 months.
This means that RLAY's stock price may go up by +821.43% over the next 12 months.
We can't find any ETFs which contains Relay Therapeutics Inc's stock.
As per our most recent records Relay Therapeutics Inc has 261 Employees.
Relay Therapeutics Inc's registered address is 399 Binney Street, Cambridge, MA, United States, 02139.
You can get more information about it from Relay Therapeutics Inc's website at https://www.relaytx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Relay Therapeutics Inc (RLAY) Stock
Based on ratings from 4 analysts Relay Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 7 buy, sell and hold ratings.
Unfortunately we do not have enough data on RLAY's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for RLAY is USD 18.43 over the next 12 months. The maximum analyst target price is USD 23 while the minimum anlayst target price is USD 16.
Unfortunately we do not have enough data on RLAY's stock to indicate if its overvalued.
The last closing price of RLAY's stock was USD 2.05.
The most recent market capitalization for RLAY is USD 0.59B.
Based on targets from 4 analysts, the average taret price for RLAY is projected at USD 18.43 over the next 12 months.
This means that RLAY's stock price may go up by +821.43% over the next 12 months.
We can't find any ETFs which contains Relay Therapeutics Inc's stock.
As per our most recent records Relay Therapeutics Inc has 261 Employees.
Relay Therapeutics Inc's registered address is 399 Binney Street, Cambridge, MA, United States, 02139.
You can get more information about it from Relay Therapeutics Inc's website at https://www.relaytx.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for RLAY !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
